Ceftolozane–tazobactam for the treatment of osteomyelitis caused by multidrug-resistant pathogens: a case series

Ceftolozane–tazobactam (CT) is a recently approved novel cephalosporin and β-lactamase inhibitor combination agent with in vitro activity against various Gram-positive and Gram-negative pathogens, including several multidrug-resistant (MDR) Gram-negative organisms. CT is currently approved by the US...

Descripción completa

Detalles Bibliográficos
Autores principales: Tan, Xing, Moenster, Ryan P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2019
Materias:
Case Series
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6614941/
https://www.ncbi.nlm.nih.gov/pubmed/31312424
http://dx.doi.org/10.1177/2042098619862083

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6614941/
https://www.ncbi.nlm.nih.gov/pubmed/31312424
http://dx.doi.org/10.1177/2042098619862083

Ejemplares similares